FTC Defends Bid For Review In AbbVie Pay-For-Delay Suit
The Federal Trade Commission on Friday defended its bid to have a judge reconsider the dismissal of its pay-for-delay claims against AbbVie Inc. and other drugmakers over the testosterone drug AndroGel,...To view the full article, register now.
Already a subscriber? Click here to view full article